Ixazomib–Thalidomide–Dexamethasone for induction therapy followed by Ixazomib maintenance treatment in patients with relapsed/refractory multiple myeloma
Ludwig H, Poenisch W, Knop S, Egle A, Schreder M, Lechner D, Hajek R, Gunsilius E, Krenosz KJ, Petzer A, Weisel K, Niederwieser D, Einsele H, Willenbacher W, Melchardt T, Greil R, Zojer N (2019)
Publication Type: Journal article
Publication year: 2019
Journal
Book Volume: 121
Pages Range: 751-757
Journal Issue: 9
DOI: 10.1038/s41416-019-0581-8
Abstract
Background: Ixazomib-revlimid-dexamethason showed significant activity in relapsed/refractory multiple myeloma (RRMM). Here, we evaluate ixazomib in combination with thalidomide and dexamethasone for induction treatment followed by ixazomib maintenance therapy in RRMM patients. Methods: Ninety patients have been included. Ixazomib–thalidomide–dexamethasone (4 mg, day 1, 8, 15; 100 mg daily; and 40 mg weekly) was scheduled for eight cycles followed by maintenance with ixazomib for one year. Results: The overall response rate was 51.1%, 23.3% achieved CR or VGPR and 10% MR resulting in a clinical benefit rate of 61.1%. In patients completing ≥2 cycles, the rates were 60.5%, 27.6% and 68.4%, respectively. Median progression-free survival (PFS) was 8.5 months in all, and 9.4 months in those completing ≥2 cycles. Response rates, PFS and overall survival (OS) were similar in patients with and without t(4;14) and/or del(17p), but PFS and OS was significantly shorter in patients with gain of 1q21. Multivariate regression analysis revealed gain of 1q21 as the most important factor associated with OS. Ixazomib maintenance resulted in an upgrade in the depth of response in 12.4% of patients. Grade 3/4 toxicities were relatively rare. Conclusions: Ixazomib–thalidomide–dexamethasone followed by ixazomib maintenance therapy is active and well tolerated in patients with RRMM. Trial registration number: NCT02410694.
Involved external institutions
Wilhelminenspital
Austria (AT)
Ordensklinikum Linz - Elisabethinen
Austria (AT)
University Hospital Ostrava / Fakultní Nemocnice Ostrava
Czech Republic (CZ)
Paracelsus Medizinische Privatuniversität
Austria (AT)
Universität Leipzig
Germany (DE)
Julius-Maximilians-Universität Würzburg
Germany (DE)
Medizinische Universität Innsbruck
Austria (AT)
Kepler Universitätsklinikum (KUK)
Austria (AT)
Ordensklinikum Linz GmbH Barmherzige Schwestern
Austria (AT)
Universitätsklinikum Hamburg-Eppendorf (UKE)
Germany (DE)
Austria (AT)
Ordensklinikum Linz - Elisabethinen
Austria (AT)
University Hospital Ostrava / Fakultní Nemocnice Ostrava
Czech Republic (CZ)
Paracelsus Medizinische Privatuniversität
Austria (AT)
Universität Leipzig
Germany (DE)
Julius-Maximilians-Universität Würzburg
Germany (DE)
Medizinische Universität Innsbruck
Austria (AT)
Kepler Universitätsklinikum (KUK)
Austria (AT)
Ordensklinikum Linz GmbH Barmherzige Schwestern
Austria (AT)
Universitätsklinikum Hamburg-Eppendorf (UKE)
Germany (DE)
How to cite
APA:
Ludwig, H., Poenisch, W., Knop, S., Egle, A., Schreder, M., Lechner, D.,... Zojer, N. (2019). Ixazomib–Thalidomide–Dexamethasone for induction therapy followed by Ixazomib maintenance treatment in patients with relapsed/refractory multiple myeloma. British Journal of Cancer, 121(9), 751-757. https://doi.org/10.1038/s41416-019-0581-8
MLA:
Ludwig, Heinz, et al. "Ixazomib–Thalidomide–Dexamethasone for induction therapy followed by Ixazomib maintenance treatment in patients with relapsed/refractory multiple myeloma." British Journal of Cancer 121.9 (2019): 751-757.
BibTeX: Download